Terminology for sample collection in clinical genetic studies
The Pharmacogenetics Working Group* In a clinical research program involving genetic analysis, the taking of a blood or tissue sample for analysis may be the first and only physical involvement of a subject in the genetic aspects of the study. This sample therefore is a key link between the subject, the subject's medical record, and the results of genetic analysis. The processes by which the samples might be stored, coded, archived, or transferred to others, and under which the results related to that sample are disclosed and used are critical to the relationship between the subject, researchers, and research sponsors. These processes have consequences for patient privacy, sample access and control, gene discovery, drug development, and product registration and regulation. Therefore, with the increase in the number of clinical trials with a genetic component and the advances in technology for rapid analysis of DNA sequences, DNA sampling has received considerable attention. Genetic information is a sensitive subject in the medical and scientific community and in the public generally. There is concern that individual genetic data could be used to discriminate against a subject in areas such as insurance or employment. Also, patients, their relatives, and their physicians worry about receiving information that is difficult to interpret and for which there is no commonly understood course of action. The specific processes for collecting, storing, and using DNA samples are key both to adequately protecting the subjects of clinical *The authors comprising The Pharmacogenetics Working Group are listed in an Appendix at the end of this article.
investigations and to enabling trials that may increase medical knowledge and develop new and more beneficial therapies.
Several ethical, regulatory, medical, and scientific bodies have described or defined processes for DNA sample collection in clinical research. In these processes, a clinical trial subject's medical information and the subject's sample are associated to meet the needs of medical research while protecting the rights of the research subjects. [1] [2] [3] [4] [5] Unfortunately, in several cases, the terminologies elaborated in different publications are at odds with one another. The same term, for instance, 'anonymous', may have significantly different meanings in different publications. Conversely, the same process might be called 'anonymous' in one case and 'unlinked' in another (for examples see Refs 1 and 3).
It is critical that everyone dealing with genetic analyses in clinical trials has a common language describing processes by which samples will be collected and handled. With a common understanding of terms, it should be possible to more readily discuss and evaluate these processes and understand their uses in specific clinical trials. The interested parties are diverse and include patients and other donors, clinical investigators, pharmaceutical company sponsors, testing laboratories, governmental agencies, bioethicists, regulatory authorities and independent ethical committees/ institutional review boards. To foster better communication, the Pharmacogenetics Working Group has considered the different terminologies related to the collection of human samples for genetic research and produced a set of terms that can meet the needs of the parties involved. The Pharmacogenetics Working Group 6 is a voluntary association of companies involved in clinical trials and genotyping whose goal is to advance the understanding and development of pharmacogenetics by addressing noncompetitive ethical, regulatory, and legal issues. In this communication, we define five different categories for the labeling and coding of genetic samples and data. The processes so defined all represent practices currently in use. The process by which a sample is taken, labeled or stored has a direct effect on how the sample can be used in the future and on the obligations of the investigator and sponsor to the sample donor. This pertains particularly to a donor's withdrawal of his or her sample or data from the study, return of information to the donor or the donor's physician, involvement of a donor's sample in future clinical investigations, and use of data for submission of regulatory filings. Additionally, the degree to which a subject would or would not want to take part in a study may be affected by such factors as the uses of the results, the nature of the information the subject might receive, and the perceived risk resulting from disclosure of genetic information to third parties. This communication will address the potential consequences of the different approaches to labeling and coding of samples or data that might be used in clinical trials. The intent of this paper is two-fold. The first is to bring more consistency to the language used in regard to clinical genetic studies, and the second is to assist regulatory bodies, institutional review boards or independent ethics committees and other interested parties in understanding the basis for an investigator's or sponsor's choice of sample category in the design of a particular study.
For the purposes of this discussion, 'Investigator' means a person respon-sible for the conduct of the clinical trial at a trial site. An investigator may be the same as or different from a genetic researcher who carries out genetic analysis on the DNA samples. 'Sponsor' means an individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial. The sponsor may be an individual, pharmaceutical company, governmental agency, academic institution, private organization, or other entity. In the conduct of pharmacogenetics research, each patient would be fully informed of the risks and benefits of the research, and appropriate informed consent should be given. 
CATEGORIES FOR GENETIC RESEARCH SAMPLES/DATA

DISCUSSION
Identified samples are treated in much the same way as samples acquired in everyday medical practice. Because the sample and the data generated from it are directly traced to the donor, it is easy to withdraw the sample or the data from the study, update patient information, and return results to the patient. Also, auditing of the study, for instance for regulatory purposes, does not present a problem. On the other hand, since a subject's genotyping results are directly linked to the subject's identity, the use of identified samples offers little privacy.
Coded samples introduce a step to separate the subject's identity from the results of the genetic analysis, much like the current practices generally used in clinical trials. The genetic researcher with knowledge of the genetic data would not have ready access to the identity of the subject, offering additional protection from casual connection between the result and the subject's name. Since the subject's identity can be revealed by breaking the code, it is possible to withdraw a subject's sample or data, update patient information, or return individual results to the subject or physician if desired. The maintenance of a link between the subject and the genetic information allows for auditing of data for regulatory purposes. Because the investigator who has coded the sample might also have access to the genetic data, the safeguards of the subject's privacy, including doctor-patient confidentiality, are equivalent to those in current clinical trials practices.
De-identified samples have an additional privacy safeguard imposed by the use of a second coding system. In this way, anyone with knowledge of the genetic results can only trace a subject's identity to a coded identifier but no further, unless a key is used to link the codes between the dataset with patient identifiers and the dataset containing the genetic information. The key to the code might be maintained by the sponsoring organization, in areas normally entrusted with maintaining confidential information (eg legal, quality assurance, clinical statistics) under strict operating procedures. Alternatively, the key might be held by an external entity, such as governmental agency, legal counsel, or other qualified third party not involved with the research. As with coded samples, the existence of a link between the genetic data and the subject's identity makes it possible to withdraw a sample or data (up to the time the results stemming from that data are reported), update patient information, return results, and audit the study to determine that genetic data are accurately correlated to a specific medical record. The individual patient medical record may be an important component of data for submission to regulatory agencies.
7-9 The conditions under which the genetic information might be linked back to the subject's identity for any purpose are determined strictly by the specifics of the research protocol. These conditions should be explicitly described in each protocol, and included within the subject's informed consent.
Anonymized samples differ from deidentified samples in that the key linking the first and second codes is deleted. Once the key has been deleted, information related to the patient's identity is no longer linked to data related to the genotyping results. Anonymization offers the maximum achievable level of security for detailed genotype-phenotype correlative analyses. However, once the linkage between the clinical data code and the genetic data code has been deleted, the possible actions related to the sample and genetic data become more limited. For instance, it will not be possible to withdraw a subject's sample or data from the analysis, to update patient information, or to return any individual results to the subject or the subject's physician. Similarly, it also is not possible to audit the study to determine that genetic data are accurately correlated to a specific subject. It is recognized that unique patient clinical data could potentially be used to reconstruct a link between a patient's medical record and genotype information. Such reconstruction would be impermissible under the protocol and standard operating procedures of a study that specifies anonymized samples. In general, anonymized samples are well suited to research studies in which hypotheses are generated and tested, but may be less so for clinical trials on which label claims are based. Finally, anonymous samples are useful in some types of genetic studies. Anonymous samples have neither personal data nor individual clinical information that could allow the identity of the donor to be traced. Names, if recorded at all, are removed permanently, and the clinical information is limited to categories of data, such as 'male, age 50-55, cholesterol Ͻ 240 mg dl −1 '. In many instances, the sample has no clinical data at all.
The choice of which category is most appropriate for a particular study depends on the nature of the research, the intended use of the data, the regulatory and legal environment, and the specific concerns of the investigator and study sponsor (Table 1) . Generally, the greater the subject privacy in a study, the less is the opportunity for the subject to withdraw or to receive individual results from the study. Privacy of information, control over use of samples, and knowledge of study results may all contribute to a subject's desire to take part in a study, and so the choice of process may significantly affect enrollment in a clinical trial. Additionally, the ability for a sponsor www.nature.com/tpj or regulatory agency to audit a study is inconsistent with complete anonymity of the subject. In designing clinical trials, investigators and sponsors are attempting to find the optimal balance between potentially conflicting goals of regulatory bodies, ethics committees, trial subjects, and researchers in order to maximize the safety and privacy of subjects and achieve the aims of the study.
